{"entity":{"id":"ilixadencel","kind":"drug","name":"Ilixadencel","aka":["Intuvax","COMBIG-DC"],"tldr":"Ilixadencel is an experimental allogeneic dendritic cell product injected into the tumour from Mendus, in phase 2 trials for metastatic renal cell carcinoma, hepatocellular carcinoma and gastrointestinal stromal tumour and other cancers; its current status is not stated.","summary":"Ilixadencel (Intuvax, COMBIG-DC) is an allogeneic dendritic cell product injected into the tumour from Mendus. Allogeneic dendritic cells injected directly into the tumour to start an immune response. Its furthest stage is phase 2, for metastatic renal cell carcinoma, hepatocellular carcinoma, gastrointestinal stromal tumour and head and neck, gastric and non-small cell lung cancer (with pembrolizumab). ClinicalTrials.gov registers it in 4 studies linked below. Phase 2 in newly diagnosed metastatic renal cell carcinoma (NCT02432846) completed; phase 1 with pembrolizumab (NCT03735290) terminated. No current development statement found on the company site. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Mendus: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT02432846"},{"label":"Mendus: mendus.com","url":"https://www.mendus.com/what-we-do/"},{"label":"ClinicalTrials.gov: trials of ilixadencel","url":"https://clinicaltrials.gov/search?intr=ilixadencel"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc","hcc","gist","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["mendus"],"institutions":[],"pathways":[],"terms":[],"trials":["nct02432846","nct01974661","nct02686944","nct03735290"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ilixadencel","modality":"Allogeneic dendritic cell product injected into the tumour","mechanism":"Allogeneic dendritic cells injected directly into the tumour to start an immune response.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ilixadencel/","neighbours":{"cancer":[{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"company":[{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/"}],"trial":[{"id":"nct03735290","kind":"trial","name":"A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer","route":"/trials/nct03735290/"},{"id":"nct02686944","kind":"trial","name":"A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors","route":"/trials/nct02686944/"},{"id":"nct02432846","kind":"trial","name":"Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)","route":"/trials/nct02432846/"},{"id":"nct01974661","kind":"trial","name":"Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma","route":"/trials/nct01974661/"}]}}